Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Mantle Cell Lymphoma Clinical Trials

13 recruiting trials for Mantle Cell Lymphoma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
13
Total Trials
13
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGPhase 2NCT03314974

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or,...

Sponsor: Masonic Cancer Center, University of MinnesotaEnrolling: 3001 location
RECRUITINGNCT03501576

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

This clinical trial evaluates the influenza virus vaccination in evaluating human immune response in patients with lymphoma. Evaluating immune response may increase the...

Sponsor: Emory UniversityEnrolling: 2002 locations
RECRUITINGPhase 1NCT04775745

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed...

Sponsor: Newave Pharmaceutical IncEnrolling: 604 locations
RECRUITINGPhase 1NCT05887167

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor...

The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with...

Sponsor: Joshua Sasine, MD, PhDEnrolling: 201 location
RECRUITINGPhase 2NCT06300528

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

The purpose of this clinical trial is to learn if the study drug pemigatinib is effective in treating patients with relapsed or refractory B-cell non-Hodgkin lymphomas.

Sponsor: University of UtahEnrolling: 271 location
RECRUITINGPhase 3NCT07377578

A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle...

Mantle cell lymphoma (MCL) is an aggressive yet often indolent type of B-cell non-Hodgkin lymphoma (NHL). Rocbrutinib (LP-168) is a novel, highly selective, fourth-generation...

Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.Enrolling: 3942 locations
RECRUITINGPhase 1NCT06026319

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated...

Sponsor: Marcela V. Maus, M.D.,Ph.D.Enrolling: 241 location
RECRUITINGPhase 2NCT06341556

A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma

This study aims to evaluate whether maintenance therapy with Zanubrutinib monotherapy could improve the 2-year progression free survival (PFS) of patients with mantle cell...

Sponsor: Fudan UniversityEnrolling: 522 locations
RECRUITINGPhase 2NCT06854003

BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN)...

This study aims to evaluate the efficacy and safety of an induction regimen combining Bendamustine, Rituximab, Cytarabine (AraC), and Zanubrutinib (BRAZAN), followed by...

Sponsor: Christine RyanEnrolling: 607 locations
RECRUITINGNCT06852638

CD70-targeted immunoPET Imaging of Malignant Cancers

This study aims to establish and optimize the cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and...

Sponsor: RenJi HospitalEnrolling: 3001 location
RECRUITINGNCT01962636

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases,...

Sponsor: Masonic Cancer Center, University of MinnesotaEnrolling: 2001 location
RECRUITINGNCT06784167

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as...

Sponsor: OHSU Knight Cancer InstituteEnrolling: 451 location
RECRUITINGPhase 2NCT07285044

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve...

This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer...

Sponsor: Mayo ClinicEnrolling: 271 location